Nirav Shah

49PUBLICATIONS
215CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (49)

|Sep 24, 2026
Risk factors for CRS and ICANS with Bispecific Antibodies for Aggressive Lymphomas.

|Aug 14, 2026
Treatment, Monitoring, and Management of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Evidence From a Multi-Country Needs Assessment.

|Jul 28, 2026
Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.

|Jun 22, 2026
Itacitinib plus calcineurin inhibitor-based therapy for prophylaxis of graft-versus-host disease: GRAVITAS-119 results.

|Jun 12, 2026
A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma.

|Feb 03, 2026
Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Lyndsey Runaas, Salena Fank, Katie Palen

Pageof 9

Frequent Collaborators

12 joint publications

Mehdi Hamadani

10 joint publications

Shuo Ma

9 joint publications

Narendranath Epperla

7 joint publications

Jonathon B Cohen